Larimar Therapeutics reported a net loss of $62.5 million ($0.73 per share) for the fourth quarter of 2025 and $165.7 million ($2.27 per share) for the full year. Cash, cash equivalents, and marketable securities totaled $136.9 million as of December 31, 2025, and the February 2026 public offering added $107.6 million, bringing the pro‑forma cash balance to $244.5 million and extending the runway into the second quarter of 2027.
The quarter’s loss was driven by a $59.4 million increase in research and development expenses, largely from $30.4 million in nomlabofusp manufacturing costs and $1.5 million in clinical study costs. General and administrative expenses rose modestly to $4.6 million, while other income fell to $1.5 million from $2.5 million in the prior year quarter. Full‑year 2025 R&D expense of $154.2 million reflected a $63.3 million jump in manufacturing costs and $6.3 million in clinical study costs.
CEO Carole Ben‑Maimon highlighted the company’s progress, noting that the Breakthrough Therapy designation for nomlabofusp underscores the unmet need in Friedreich’s ataxia and that the company remains on track to submit a Biologics License Application in June 2026. She also emphasized that the recent financing strengthens the balance sheet and provides a runway to execute the planned Phase 3 study.
Analysts had estimated a fourth‑quarter loss of $0.44 per share; Larimar reported a loss of $0.73 per share, missing consensus by $0.29 per share. The full‑year loss also fell short of expectations, with analysts projecting a $2.10 loss per share.
Investors view the extended cash runway and regulatory milestones as key tailwinds, but the pre‑revenue status and continued need for capital raises remain headwinds. The company’s focus on advancing nomlabofusp through Phase 3 and the planned BLA submission positions it for a potential launch in the first half of 2027, while the need for future funding underscores the high‑risk nature of the business.
Overall, the earnings release confirms Larimar’s continued investment in its lead candidate and the financial resources required to reach regulatory milestones, but it also highlights the ongoing challenge of sustaining operations without revenue and the likelihood of additional capital raises in the near future.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.